Supernus Financial Statements From 2010 to 2024
| SUPN Stock | USD 30.27 0.19 0.63% |
Gross Profit 580 M | Profit Margin 0.0022 | Market Capitalization 1.7 B | Enterprise Value Revenue 2.3733 | Revenue 607.5 M |
Supernus Pharmaceuticals Total Revenue |
|
Check Supernus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Supernus main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.1 M, Interest Expense of 2.3 M or Total Revenue of 637.9 M, as well as many exotic indicators such as Price To Sales Ratio of 2.47, Dividend Yield of 0.0 or PTB Ratio of 1.51. Supernus financial statements analysis is a perfect complement when working with Supernus Pharmaceuticals Valuation or Volatility modules.
Supernus | Select Account or Indicator |
Supernus Pharmaceuticals Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supernus Pharmaceuticals Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supernus Pharmaceuticals Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supernus Pharmaceuticals Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supernus Fundamental Market Drivers
| Forward Price Earnings | 20.1613 | |
| Cash And Short Term Investments | 254.9 M |
Supernus Upcoming Events
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
About Supernus Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Supernus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Supernus Pharmaceuticals investors use historical funamental indicators, such as Supernus Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Supernus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Supernus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Supernus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Supernus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Supernus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.00 | 0.95 | |
| Total Revenue | 607.5 M | 637.9 M | |
| Cost Of Revenue | 168.6 M | 177.1 M | |
| Stock Based Compensation To Revenue | 0.04 | 0.04 | |
| Sales General And Administrative To Revenue | 0.18 | 0.17 | |
| Research And Ddevelopement To Revenue | 0.15 | 0.14 | |
| Capex To Revenue | (0.0009) | (0.001) | |
| Revenue Per Share | 11.14 | 11.70 | |
| Ebit Per Revenue | 0.02 | 0.02 |
Currently Active Assets on Macroaxis
| LAAC | Lithium Americas Corp | |
| F | Ford Motor | |
| CHPT | ChargePoint Holdings | |
| AXL | American Axle Manufacturing | |
| ICLN | iShares Global Clean |
Check out the analysis of Supernus Pharmaceuticals Correlation against competitors. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.